scholarly journals Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension

2017 ◽  
Vol 81 (9) ◽  
pp. 1360-1367 ◽  
Author(s):  
Nobuhiro Tanabe ◽  
Satoshi Ikeda ◽  
Nobuhiro Tahara ◽  
Keiichi Fukuda ◽  
Masaru Hatano ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Prostacyclin Receptor ◽  
Pulmonary Arterial

scholarly journals Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension　– Insights From the IBUKI and AIR Studies –

2016 ◽  
Vol 80 (4) ◽  
pp. 835-842 ◽  
Author(s):  
Tsutomu Saji ◽  
Masafumi Myoishi ◽  
Koichiro Sugimura ◽  
Nobuhiro Tahara ◽  
Yutaka Takeda ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Inhaled Iloprost ◽  
Pulmonary Arterial

scholarly journals Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension

2015 ◽  
Vol 58 (18) ◽  
pp. 7128-7137 ◽  
Author(s):  
Tetsuo Asaki ◽  
Keiichi Kuwano ◽  
Keith Morrison ◽  
John Gatfield ◽  
Taisuke Hamamoto ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Prostacyclin Receptor ◽  
Pulmonary Arterial

scholarly journals Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report

2021 ◽  
Vol 20 (5) ◽  
pp. 3010
Author(s):  
E. A. Rezukhina ◽  
O. V. Rodnenkov ◽  
T. V. Martynyuk
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
High Risk ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
World Health ◽  
Class Iii ◽  
National Medical ◽  
Prostacyclin Receptor ◽  
Pulmonary Arterial

We present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology due to increase in exercise dyspnea and decrease in effort tolerance. According to a comprehensive examination, single factors of high risk and unfavorable prognosis were identified. Due to systemic hypotension when using inhaled iloprost, selexipag was added to therapy. According to control hospitalization, 8-month selexipag therapy improved the patient's condition, as well as high risk factors were not revealed. Selexipag is a selective oral prostacyclin receptor agonist recommended for longterm IPAH therapy in adult patients.

scholarly journals Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

2012 ◽  
Vol 40 (4) ◽  
pp. 874-880 ◽  
Author(s):  
Gérald Simonneau ◽  
Adam Torbicki ◽  
Marius M. Hoeper ◽  
Marion Delcroix ◽  
Kristóf Karlócai ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Prostacyclin Receptor ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document